Skip to main content

La industria biofarmacéutica y la sociedad

Healthcare
United States
Iniciada April 22, 2026

The Bio-Pharma Industry and Society Listing Summary Please join the CSIS Global Health Policy Center on March 17, from 10:00am – 11:30am, for an exploration of how private bio-pharmaceutical firms can better support the critically important societal goals of improved affordability, access, quality, and innovation. Drupal Admin Thu, 03/03/2016 - 15:36 Featured Image Image Contributors J. Stephen Morrison Downloads Download Transcript Here Document 160317_The_Bio-Pharma_Industry_and_Society_Tra...

Artículos de Fuentes

The Bio-Pharma Industry and Society

CSIS (United States) | Mar 03, 2016

Need to find a specific claim? Search all statements.
🗳️ Join the conversation
5 afirmaciones para votar • Your perspective shapes the analysis
📊 Progress to Consensus Analysis Need: 7+ participants, 20+ votes, 3+ votes per statement
Participants 0/7
Statements (7+ recommended) 5/7
Total Votes 0/20
💡 Progress updates live here. Final readiness is confirmed when all three requirements are met.

Your votes count

No account needed — your votes are saved and included in the consensus analysis. Create an account to track your voting history and add statements.

CLAIM Publicado por will Apr 22, 2026
La industria biofarmacéutica debe priorizar la asequibilidad y el acceso para garantizar que los medicamentos que salvan vidas estén disponibles para todos, no solo para los ricos.
Traducido por IA · Ver original

The bio-pharma industry must prioritize affordability and access to ensure that life-saving medications are available to all, not just the wealthy.

Vote options for this statement: agree, disagree, or unsure
Vote to see results
CLAIM Publicado por will Apr 22, 2026
Aunque la innovación es crucial, la búsqueda incesante de ganancias en el sector biofarmacéutico a menudo conduce a precios de medicamentos inflados, socavando la salud pública.
Traducido por IA · Ver original

While innovation is crucial, the relentless pursuit of profit in the bio-pharma sector often leads to inflated drug prices, undermining public health.

Vote options for this statement: agree, disagree, or unsure
Vote to see results
CLAIM Publicado por will Apr 22, 2026
El enfoque en la innovación rápida en la industria biofarmacéutica puede comprometer la calidad y la seguridad de los medicamentos, generando riesgos para los pacientes.
Traducido por IA · Ver original

The focus on rapid innovation in the bio-pharma industry can compromise the quality and safety of medications, posing risks to patients.

Vote options for this statement: agree, disagree, or unsure
Vote to see results
CLAIM Publicado por will Apr 22, 2026
Las asociaciones público-privadas en el sector biofarmacéutico pueden mejorar la investigación y el desarrollo, dando lugar a avances que benefician a la sociedad en su conjunto.
Traducido por IA · Ver original

Public-private partnerships in the bio-pharma sector can enhance research and development, leading to breakthroughs that benefit society as a whole.

Vote options for this statement: agree, disagree, or unsure
Vote to see results
CLAIM Publicado por will Apr 22, 2026
Es necesario un enfoque equilibrado; la industria biofarmacéutica puede impulsar la innovación mientras aborda también cuestiones de acceso y asequibilidad.
Traducido por IA · Ver original

A balanced approach is necessary; the bio-pharma industry can drive innovation while also addressing issues of access and affordability.

Vote options for this statement: agree, disagree, or unsure
Vote to see results

💡 How This Works

  • Add Statements: Post claims or questions (10-500 characters)
  • Vote: Agree, Disagree, or Unsure on each statement
  • Respond: Add detailed pro/con responses with evidence
  • Consensus: After enough participation, analysis reveals opinion groups and areas of agreement

Society Speaks is open and independent. Your support keeps civic discussion free from advertising and commercial influence.

Support us